What is UNITY BIOTECHNOLOGY INC's earnings per share (EPS)?

UNITY BIOTECHNOLOGY INC (UNBX) reported diluted earnings per share of -$1.54 for fiscal year 2024. This represents a 43.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

UNITY BIOTECHNOLOGY INC (UNBX) Financials

UNBX

FY2024 annual

Revenue $0 YoY not available

Net Income -$26.0M +34.8% YoY

EPS (Diluted) -$1.54 +43.0% YoY

Free Cash Flow -$20.9M +43.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2025, ended Mar 31, 2025 Reported Apr 22, 2025 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2025, filed Apr 22, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the UNBX SEC filings page.

UNITY BIOTECHNOLOGY INC (UNBX) reported $0 in revenue for fiscal year 2024. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI UNBX FY2024 2026-08-30

UNBX remains development-stage: reduced R&D spending has narrowed cash requirements, but operating losses still consume capital.

FY2024 operating cash flow was -$20.9M versus net loss of -$26.0M, a relatively tight gap indicating that the loss was mostly cash-operating economics rather than non-cash accounting charges. With capital expenditures at $0, free cash flow essentially tracked operating cash flow, so the cash shortfall was not being driven by expansionary reinvestment.

R&D fell from $36.9M in FY2022 to $13.0M in FY2024, and SG&A also declined, showing a broad pullback in spending rather than a single cost line being trimmed. Yet FY2024 operating income remained -$31.2M, implying that lower investment reduced the loss without producing an operating model that had reached self-funding economics.

Equity fell from $28.4M in FY2023 to $6.5M in FY2024. That compression pushed debt-to-equity from 0.0x to 4.8x; because long-term debt is not reported for FY2024, the ratio mainly signals a thinner equity cushion, not necessarily new borrowing.

Financial Health Signals

Financial health score not available

UNITY BIOTECHNOLOGY INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

UNITY BIOTECHNOLOGY INC passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

UNITY BIOTECHNOLOGY INC reported a net loss of $26.0M while operations used $20.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

UNITY BIOTECHNOLOGY INC generated $0 in revenue in Q1 2025.

EBITDA

-$6.7M

YoY+8.9%

UNITY BIOTECHNOLOGY INC's EBITDA was -$6.7M in Q1 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.9% from the same quarter a year earlier.

Net Income

-$7.3M

YoY-26.1%

UNITY BIOTECHNOLOGY INC reported -$7.3M in net income in Q1 2025. This represents a decrease of 26.1% from the same quarter a year earlier.

EPS (Diluted)

-$0.43

YoY-26.5%

QoQ+14.0%

UNITY BIOTECHNOLOGY INC earned -$0.43 per diluted share (EPS) in Q1 2025. This represents a decrease of 26.5% from the same quarter a year earlier. Against the prior quarter it is up 14.0%.

Cash & Balance Sheet

Cash & Debt

$8.0M

YoY+7.7%

QoQ+5.5%

5Y CAGR-20.4%

UNITY BIOTECHNOLOGY INC held $8.0M in cash as of Q1 2025; long-term debt is not reported for that period.

Shares Outstanding

17M

YoY+2.5%

QoQ+2.0%

5Y CAGR-18.9%

UNITY BIOTECHNOLOGY INC had 17M shares outstanding in Q1 2025. This represents an increase of 2.5% from the same quarter a year earlier. Against the prior quarter it is up 2.0%.

Free Cash Flow

Not reported for Q1 2025.

Dividends Per Share

Not reported for Q1 2025.

Margins & Returns

None of these metrics is reported for Q1 2025.

Capital Allocation

R&D Spending

$2.8M

YoY-25.5%

UNITY BIOTECHNOLOGY INC invested $2.8M in research and development in Q1 2025. This represents a decrease of 25.5% from the same quarter a year earlier.

Share Buybacks

Not reported for Q1 2025.

Capital Expenditures

Not reported for Q1 2025.

UNBX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UNBX quarterly income statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Revenue	N/A	$0	$0-100.0%	$236K-95.1%	$4.8M	$0	$0	N/A	N/A	N/A
R&D Expenses	N/A	$13.0M-35.3%	$20.1M-45.5%	$36.9M-4.0%	$38.4M-43.0%	$67.3M-5.1%	$71.0M+20.5%	$58.9M+57.6%	$37.4M+172.7%	$13.7M
SG&A Expenses	N/A	$15.5M-18.5%	$19.0M-9.5%	$20.9M-9.1%	$23.1M-4.0%	$24.0M+19.8%	$20.0M+25.2%	$16.0M+66.5%	$9.6M+87.2%	$5.1M
Operating Income	N/A	-$31.2M+30.2%	-$44.7M+22.4%	-$57.6M-1.6%	-$56.7M+39.7%	-$93.9M-4.8%	-$89.7M-12.8%	-$79.5M-74.2%	-$45.6M-142.0%	-$18.8M
EBITDA	N/A	-$30.3M+30.3%	-$43.5M+21.5%	-$55.4M-3.0%	-$53.8M+40.6%	-$90.5M-4.0%	-$87.0M-12.6%	-$77.3M-74.4%	-$44.3M-137.0%	-$18.7M
Interest Expense	N/A	$0-100.0%	$2.5M-31.1%	$3.6M+12.0%	$3.2M+145.9%	$1.3M	$0	N/A	N/A	$2.2M
Net Income	N/A	-$26.0M+34.8%	-$39.9M+10.4%	-$44.5M+26.8%	-$60.7M+35.3%	-$93.8M-14.2%	-$82.2M-7.6%	-$76.4M-71.1%	-$44.7M-46.9%	-$30.4M
EPS (Basic)	N/A	-$1.54+43.0%	-$2.70+42.3%	-$4.68+57.0%	-$10.88+41.0%	-$18.45	N/A	N/A	N/A	N/A
EPS (Diluted)	-$1.62	-$1.54+43.0%	-$2.70	-$4.68	-$10.88+41.0%	-$18.45	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	17M+13.9%	15M	9M	6M+9.7%	5M	N/A	N/A	N/A	N/A

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-K
Revenue	$0	N/A	N/A	N/A	$0	N/A	N/A	$0-100.0%
R&D Expenses	$2.8M-25.5%	N/A	$2.8M-39.8%	$3.5M-46.2%	$3.7M-35.4%	N/A	$4.6M-49.0%	$6.4M-14.8%
SG&A Expenses	$4.1M+6.2%	N/A	$3.8M-12.2%	$3.5M-35.0%	$3.9M-19.2%	N/A	$4.3M-11.7%	$5.4M+9.6%
Operating Income	-$6.9M+9.3%	N/A	-$6.6M+54.7%	-$7.0M+41.1%	-$7.6M+28.0%	N/A	-$14.6M-4.1%	-$11.8M+3.3%
EBITDA	-$6.7M+8.9%	N/A	-$6.4M+55.3%	-$6.8M+41.4%	-$7.4M+27.9%	N/A	-$14.3M-5.9%	-$11.5M+1.0%
Interest Expense	N/A	N/A	N/A	N/A	$0-100.0%	N/A	$566K-34.6%	$883K-1.2%
Net Income	-$7.3M-26.1%	N/A	-$6.5M+56.2%	-$5.3M+65.8%	-$5.8M-9.7%	N/A	-$14.8M-195.8%	-$15.5M-17.7%
EPS (Basic)	-$0.43-26.5%	-$0.50-108.3%	-$0.38+62.4%	-$0.31+71.0%	-$0.34+8.1%	-$0.24-2300.0%	-$1.01-102.0%	-$1.07+43.7%
EPS (Diluted)	-$0.43-26.5%	-$0.50-108.3%	-$0.38+62.4%	-$0.31+71.0%	-$0.34+8.1%	-$0.24-2300.0%	-$1.01-102.0%	-$1.07
Diluted Shares (Avg)	17M+0.5%	N/A	17M+15.4%	17M+16.6%	17M+17.3%	N/A	15M+44.9%	14M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

UNBX Balance Sheet

UNBX quarterly balance sheet

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Total Assets	$37.7M-42.7%	$65.7M-47.2%	$124.3M-0.3%	$124.7M-20.2%	$156.3M+3.4%	$151.2M-16.6%	$181.4M+77.8%	$102.0M	N/A
Current Assets	$24.3M-47.9%	$46.6M-51.7%	$96.5M+6.7%	$90.5M-10.3%	$100.9M-22.1%	$129.5M-25.1%	$173.0M+94.6%	$88.9M	N/A
Cash & Equivalents	$7.6M-61.7%	$19.8M+55.5%	$12.7M-61.3%	$32.9M+84.8%	$17.8M-52.5%	$37.5M+143.3%	$15.4M+111.0%	$7.3M-91.8%	$89.3M
Short-Term Investments	$15.7M-33.1%	$23.4M-71.5%	$82.1M+48.7%	$55.2M-30.9%	$79.9M-5.5%	$84.5M-45.7%	$155.7M+96.6%	$79.2M	$0
Long-Term Investments	$0	$0	$0-100.0%	$2.0M-88.8%	$17.9M+490.8%	$3.0M	$0-100.0%	$5.1M	$0
Total Liabilities	$31.2M-16.4%	$37.3M-45.4%	$68.3M+4.8%	$65.1M-11.3%	$73.4M+140.7%	$30.5M+47.5%	$20.7M-88.8%	$185.1M	N/A
Current Liabilities	$9.3M+18.1%	$7.8M-60.0%	$19.6M+18.1%	$16.6M+14.9%	$14.5M-16.0%	$17.2M+3.8%	$16.6M+110.0%	$7.9M	N/A
Non-Current Liabilities	$21.9M-25.6%	$29.5M-39.5%	$48.6M+0.2%	$48.5M-17.7%	$59.0M+343.5%	$13.3M+224.3%	$4.1M-97.7%	$177.2M	N/A
Long-Term Debt	N/A	$0-100.0%	$10.9M-40.8%	$18.4M-24.9%	$24.5M	$0	N/A	N/A	N/A
Total Equity	$6.5M-77.1%	$28.4M-49.4%	$56.1M-5.9%	$59.6M-28.1%	$82.9M-31.3%	$120.7M-24.9%	$160.7M+293.3%	-$83.1M-100.1%	-$41.5M
Retained Earnings	-$510.3M-5.4%	-$484.4M-9.0%	-$444.5M-11.1%	-$400.0M-17.9%	-$339.3M-38.2%	-$245.5M-50.3%	-$163.3M-87.9%	-$86.9M	N/A

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-K
Total Assets	$30.3M-48.4%	$37.7M-42.7%	$47.1M-32.0%	$53.5M-47.0%	$58.9M-48.5%	$65.7M-47.2%	$69.3M-49.2%	$101.0M+3.5%
Current Assets	$17.6M-54.2%	$24.3M-47.9%	$30.3M-38.9%	$35.8M-50.9%	$38.5M-55.4%	$46.6M-51.7%	$49.5M-51.7%	$73.0M+7.6%
Cash & Equivalents	$8.0M+7.7%	$7.6M-61.7%	$8.9M+13.0%	$7.6M-60.3%	$7.4M-67.7%	$19.8M+55.5%	$7.9M-65.1%	$19.1M-1.7%
Short-Term Investments	$8.9M-69.1%	$15.7M-33.1%	$20.1M-47.1%	$26.4M-47.2%	$28.9M-52.2%	$23.4M-71.5%	$38.1M-50.2%	$50.0M+10.9%
Long-Term Investments	$0-100.0%	$0	$0	$0-100.0%	$2.0M	$0	$0-100.0%	$1.9M
Total Liabilities	$30.6M-12.4%	$31.2M-16.4%	$33.0M-20.6%	$33.8M-43.9%	$34.9M-42.7%	$37.3M-45.4%	$41.5M-44.7%	$60.2M+4.5%
Current Liabilities	$9.1M+17.3%	$9.3M+18.1%	$8.8M+1.7%	$8.8M-60.2%	$7.7M-64.6%	$7.8M-60.0%	$8.6M-50.7%	$22.1M+34.8%
Non-Current Liabilities	$21.5M-20.8%	$21.9M-25.6%	$24.2M-26.5%	$24.9M-34.5%	$27.1M-30.5%	$29.5M-39.5%	$32.9M-42.9%	$38.1M-7.6%
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$0-100.0%	$4.1M-67.9%
Total Equity	-$205K-100.9%	$6.5M-77.1%	$14.1M-49.0%	$19.8M-51.5%	$24.0M-55.0%	$28.4M-49.4%	$27.7M-54.6%	$40.8M+2.1%
Retained Earnings	-$517.6M-5.6%	-$510.3M-5.4%	-$501.9M-4.6%	-$495.4M-6.5%	-$490.1M-9.0%	-$484.4M-9.0%	-$480.0M-9.8%	-$465.2M-7.7%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

UNBX Cash Flow Statement

UNBX quarterly cash flow statement

Metric	TTM	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Cash Flow	-$22.0M	-$20.9M+43.7%	-$37.1M+29.2%	-$52.4M-16.3%	-$45.1M+42.5%	-$78.3M-8.2%	-$72.4M-27.9%	-$56.6M-47.6%	-$38.4M-133.9%	-$16.4M
Depreciation & Amortization	N/A	$867K-26.6%	$1.2M-45.8%	$2.2M-24.3%	$2.9M-16.5%	$3.4M+29.5%	$2.7M+22.2%	$2.2M+67.2%	$1.3M+752.3%	$153K
Stock-Based Compensation	N/A	$4.0M-46.5%	$7.4M-20.9%	$9.4M-18.8%	$11.6M-16.4%	$13.8M+27.3%	$10.9M+14.9%	$9.4M+211.2%	$3.0M+1254.5%	$224K
Capital Expenditures	N/A	$0-100.0%	$11K-88.5%	$96K-50.8%	$195K-69.8%	$646K-59.3%	$1.6M+25.5%	$1.3M-25.2%	$1.7M-24.7%	$2.2M
Free Cash Flow	N/A	-$20.9M+43.8%	-$37.1M+29.3%	-$52.5M-16.0%	-$45.3M+42.7%	-$79.0M-6.7%	-$74.0M-27.8%	-$57.9M-44.5%	-$40.0M-114.8%	-$18.6M
Investing Cash Flow	$22.5M	$8.6M-85.8%	$60.5M+346.5%	-$24.5M-162.4%	$39.3M+854.9%	-$5.2M-107.7%	$68.0M+194.1%	-$72.2M+16.3%	-$86.3M-3045.2%	-$2.7M
Financing Cash Flow	N/A	$77K+100.5%	-$16.3M-129.1%	$56.2M+169.8%	$20.8M-67.4%	$63.9M+132.8%	$27.4M-80.0%	$136.9M+220.1%	$42.8M-60.4%	$107.9M

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-K
Operating Cash Flow	-$6.4M-22.7%	-$5.9M+22.0%	-$5.2M+27.0%	-$4.6M+58.6%	-$5.2M+54.2%	-$7.6M+26.9%	-$7.1M+41.9%	-$11.1M+25.3%
Depreciation & Amortization	$178K-21.6%	$203K-12.1%	$216K-29.9%	$221K-29.6%	$227K-31.0%	$231K-43.5%	$308K-42.4%	$314K-48.4%
Stock-Based Compensation	$617K-55.7%	N/A	$797K-53.3%	$974K-56.7%	$1.4M-35.9%	N/A	$1.7M-22.9%	$2.2M-0.1%
Capital Expenditures	N/A	$0	N/A	N/A	N/A	$0-100.0%	$11K-77.1%	N/A
Free Cash Flow	N/A	-$5.9M+22.0%	N/A	N/A	N/A	-$7.6M+27.2%	-$7.1M+42.0%	N/A
Investing Cash Flow	$6.8M+194.2%	$4.6M-69.7%	$6.5M-54.3%	$4.7M-52.6%	-$7.2M-133.8%	$15.1M+8013.1%	$14.2M+139.3%	$9.9M-44.3%
Financing Cash Flow	N/A	$9K-99.8%	$0+100.0%	$68K+102.6%	$0-100.0%	$4.4M+2527.5%	-$18.4M-135.6%	-$2.6M-2002.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

UNBX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

UNBX quarterly financial ratios

Metric	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K
Operating Margin	N/A	N/A	-24394.9%	-1184.5%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	-18842.8%	-1269.3%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-400.2%-259.9pp	-140.4%-61.1pp	-79.3%+22.7pp	-101.9%+11.3pp	-113.2%-45.2pp	-68.1%-20.5pp	-47.5%	N/A	N/A
Return on Assets	-69.0%-8.3pp	-60.7%-24.9pp	-35.8%+12.9pp	-48.7%+11.3pp	-60.0%-5.7pp	-54.3%-12.2pp	-42.1%+1.6pp	-43.8%	N/A
Current Ratio	2.62-3.3x	5.94+1.0x	4.92-0.5x	5.45-1.5x	6.97-0.5x	7.52-2.9x	10.43-0.8x	11.25	N/A
Debt-to-Equity	4.80+4.8x	0.00-0.2x	0.19-0.1x	0.310.0x	0.30+0.3x	0.00-0.1x	0.13	N/A	N/A
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.040.0x	0.000.0x	0.00	N/A	N/A	N/A
FCF Margin	N/A	N/A	-22250.0%	-946.0%	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2510-Q	Q4'2410-Q	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-K
Return on Equity	N/A	N/A	-45.8%+7.5pp	-26.7%+11.2pp	-24.1%-14.3pp	N/A	-53.3%-45.1pp	-37.9%-5.0pp
Return on Assets	-24.1%-14.2pp	N/A	-13.8%+7.6pp	-9.9%+5.4pp	-9.8%-5.2pp	N/A	-21.3%-17.7pp	-15.3%-1.8pp
Current Ratio	1.95-3.0x	2.62-3.3x	3.45-2.3x	4.07+0.8x	4.98+1.0x	5.94+1.0x	5.74-0.1x	3.30-0.8x
Debt-to-Equity	N/A	4.80+4.8x	2.33+2.3x	1.71+1.6x	1.45+1.3x	0.00-0.2x	0.00-0.2x	0.10-0.2x
Asset Turnover	0.000.0x	N/A	N/A	N/A	0.000.0x	N/A	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Where UNITY BIOTECHNOLOGY INC Ranks

Frequently Asked Questions

What is UNITY BIOTECHNOLOGY INC's annual revenue?

UNITY BIOTECHNOLOGY INC (UNBX) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is UNITY BIOTECHNOLOGY INC profitable?

No, UNITY BIOTECHNOLOGY INC (UNBX) reported a net income of -$26.0M in fiscal year 2024.

What is UNITY BIOTECHNOLOGY INC's EBITDA?

UNITY BIOTECHNOLOGY INC (UNBX) had EBITDA of -$30.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is UNITY BIOTECHNOLOGY INC's return on equity (ROE)?

UNITY BIOTECHNOLOGY INC (UNBX) has a return on equity of -400.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is UNITY BIOTECHNOLOGY INC's free cash flow?

UNITY BIOTECHNOLOGY INC (UNBX) recorded an outflow of $20.9M in free cash flow during fiscal year 2024. This represents a 43.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is UNITY BIOTECHNOLOGY INC's operating cash flow?

UNITY BIOTECHNOLOGY INC (UNBX) recorded an outflow of $20.9M in operating cash flow during fiscal year 2024, representing cash used by core business activities.

What are UNITY BIOTECHNOLOGY INC's total assets?

UNITY BIOTECHNOLOGY INC (UNBX) had $37.7M in total assets as of fiscal year 2024, including both current and long-term assets.

What are UNITY BIOTECHNOLOGY INC's capital expenditures?

UNITY BIOTECHNOLOGY INC (UNBX) reported no capital expenditure during fiscal year 2024.

How much does UNITY BIOTECHNOLOGY INC spend on research and development?

UNITY BIOTECHNOLOGY INC (UNBX) invested $13.0M in research and development during fiscal year 2024.

How many shares does UNITY BIOTECHNOLOGY INC have outstanding?

UNITY BIOTECHNOLOGY INC (UNBX) had 17M shares outstanding as of fiscal year 2024.

What is UNITY BIOTECHNOLOGY INC's current ratio?

UNITY BIOTECHNOLOGY INC (UNBX) had a current ratio of 2.62 as of fiscal year 2024, which is generally considered healthy.

What is UNITY BIOTECHNOLOGY INC's debt-to-equity ratio?

UNITY BIOTECHNOLOGY INC (UNBX) had a debt-to-equity ratio of 4.80 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is UNITY BIOTECHNOLOGY INC's return on assets (ROA)?

UNITY BIOTECHNOLOGY INC (UNBX) had a return on assets of -69.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is UNITY BIOTECHNOLOGY INC's Piotroski F-Score?

UNITY BIOTECHNOLOGY INC (UNBX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are UNITY BIOTECHNOLOGY INC's earnings high quality?

UNITY BIOTECHNOLOGY INC (UNBX) reported a net loss of $26.0M while operations used $20.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.